Trekk Venture Partners
Vikas has been working in the biotech industry for 20 years, with a particular focus on corporate strategy, capital formation, corporate partnerships, and M&A for early stage therapeutics companies.
Most recently, Vikas was Senior Vice President of Business Development for Pandion Therapeutics. He initially joined Pandion as a Board member and investor in 2018, then joined the company full-time in 2019 taking the company through a research collaboration with Astellas, an IPO, and the company’s acquisition by Merck for $1.85 billion in 2021. Prior to Pandion, Vikas worked as an investor at SR One. During his time at SR One, Vikas invested in and served on the boards of 19 early stage biotech companies including Morphic Therapeutics (Nasdaq: MORF), River Vision Development (acquired by Horizon), Nimbus Therapeutics, Turning Point (acquired by BMS), Spero Therapeutics (Nasdaq: SPRO) and Pandion (acquired by Merck). River Vision and Horizon developed Tepezza™ (teprotumumab) a new standard of care in the treatment of Grave’s Orbitopathy and the first therapy ever approved for the indication.
Previously, Vikas was a Consultant at McKinsey & Co’s Pharmaceutical practice in New Jersey, a co-founder of Extera Partners, and a Business Development Manager at Infinity Pharmaceuticals.
Vikas truly believes that partnerships can be critical to the successful development of new medicines. In his free time, he hosts an interview series on the Timmerman Report with biotech business development executives about the deals they have worked on and lessons learned.
Education, Personal, and Fellowship
Vikas received his BA in neurobiology from Harvard University, and his MBA in Health Care Management from the Wharton School of the University of Pennsylvania. He lives in Somerville, MA, with his wife and two daughters.
A member of Class 17, Vikas served his fellowship at SR One under the mentorship of Jens Eckstein (Fellow Class 10).